Clinical Trials Browser

Phase 2/3 × INDUSTRY × Crizotinib × Clear all

NCT05987332 2026-02-17

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Phase 2/3 Active not recruiting

Uveal Melanoma, Melanoma